JP Morgan Chase
NSPR icon

JP Morgan Chase’s InspireMD NSPR Stock Holding History

JP Morgan Chase’s Portfolio NSPR Stock Details NSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,853
Closed -$6.48K – 7626
2025
Q2 		$6.48K Buy
+2,853
New +$7.11K ﹤0.01% 6384
2018
Q2 		– Hold
0
– – – 5638
2018
Q1 		– Hold
0
– – – 5549

Other funds holding NSPR

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

JP Morgan Chase's NSPR Position: Q3 2025 in Review

JP Morgan Chase sold out of InspireMD (NSPR) in Q3 2025, closing a stake of 2,853 shares — an estimated $6.48K sold.

JP Morgan Chase first reported a position in NSPR in Q2 2025 and held it in 1 quarter. The position peaked at $6.48K in Q2 2025. 41 funds tracked by Wall St. Rank hold NSPR as of Q3 2025.

  • JP Morgan Chase reported no remaining InspireMD position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 2,853 InspireMD shares in Q3 2025, an estimated $6.48K.
  • JP Morgan Chase first reported a position in InspireMD in Q2 2025 and held it in 1 quarter.
  • JP Morgan Chase's InspireMD position peaked at $6.48K in Q2 2025.
  • 41 funds tracked by Wall St. Rank held InspireMD as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.